Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
Werewolf Therapeutics (Nasdaq: HOWL), a biopharmaceutical company focused on developing conditionally activated therapeutics for cancer treatment and immune-mediated conditions, has announced its participation in the upcoming 2025 Leerink Partners Global Biopharma Conference.
The company's leadership, including Daniel J. Hicklin, Ph.D., President and CEO, and Randi Isaacs, M.D., Chief Medical Officer, will engage in a fireside chat scheduled for Tuesday, March 11, 2025, from 11:20-11:50 AM in Studio 3. The conference will take place in Miami, Florida, from March 10-12, 2025.
Interested parties can access a live webcast of the presentation through the company's investor relations website. The recorded session will remain available for replay for 180 days following the event.
Werewolf Therapeutics (Nasdaq: HOWL), una compagnia biofarmaceutica focalizzata nello sviluppo di terapie attivate condizionatamente per il trattamento del cancro e delle condizioni mediate dal sistema immunitario, ha annunciato la sua partecipazione alla prossima 2025 Leerink Partners Global Biopharma Conference.
La leadership dell'azienda, inclusi Daniel J. Hicklin, Ph.D., Presidente e CEO, e Randi Isaacs, M.D., Direttore Medico, parteciperà a una chiacchierata informale programmata per martedì 11 marzo 2025, dalle 11:20 alle 11:50 nel Studio 3. La conferenza si svolgerà a Miami, Florida, dal 10 al 12 marzo 2025.
Le parti interessate possono accedere a una diretta web della presentazione tramite il sito web delle relazioni con gli investitori dell'azienda. La sessione registrata rimarrà disponibile per la visione per 180 giorni dopo l'evento.
Werewolf Therapeutics (Nasdaq: HOWL), una empresa biofarmacéutica centrada en el desarrollo de terapias activadas condicionalmente para el tratamiento del cáncer y condiciones mediadas por el sistema inmunológico, ha anunciado su participación en la próxima 2025 Leerink Partners Global Biopharma Conference.
El liderazgo de la compañía, incluyendo a Daniel J. Hicklin, Ph.D., Presidente y CEO, y Randi Isaacs, M.D., Directora Médica, participará en una charla informal programada para el martes 11 de marzo de 2025, de 11:20 a 11:50 AM en el Estudio 3. La conferencia se llevará a cabo en Miami, Florida, del 10 al 12 de marzo de 2025.
Las partes interesadas pueden acceder a una transmisión en vivo de la presentación a través del sitio web de relaciones con inversionistas de la compañía. La sesión grabada estará disponible para su reproducción durante 180 días después del evento.
Werewolf Therapeutics (Nasdaq: HOWL), 암 치료 및 면역 매개 질환을 위한 조건부 활성화 치료제 개발에 집중하는 생명공학 회사가 다가오는 2025 Leerink Partners Global Biopharma Conference에 참여한다고 발표했습니다.
회사의 리더십, 즉 Daniel J. Hicklin, Ph.D., 사장 겸 CEO, Randi Isaacs, M.D., 최고 의료 책임자가 2025년 3월 11일 화요일 오전 11:20부터 11:50까지 스튜디오 3에서 예정된 파이어사이드 채팅에 참여할 예정입니다. 이 회의는 2025년 3월 10일부터 12일까지 플로리다주 마이애미에서 열립니다.
관심 있는 당사자는 회사의 투자자 관계 웹사이트를 통해 발표의 실시간 웹캐스트에 접근할 수 있습니다. 녹화된 세션은 이벤트 후 180일 동안 재생할 수 있습니다.
Werewolf Therapeutics (Nasdaq: HOWL), une entreprise biopharmaceutique axée sur le développement de thérapies activées de manière conditionnelle pour le traitement du cancer et des maladies médiées par le système immunitaire, a annoncé sa participation à la prochaine 2025 Leerink Partners Global Biopharma Conference.
La direction de l'entreprise, y compris Daniel J. Hicklin, Ph.D., Président et CEO, et Randi Isaacs, M.D., Directrice Médicale, participera à une discussion informelle prévue pour le mardi 11 mars 2025, de 11h20 à 11h50 dans le Studio 3. La conférence se déroulera à Miami, en Floride, du 10 au 12 mars 2025.
Les parties intéressées peuvent accéder à un webcast en direct de la présentation via le site web des relations avec les investisseurs de l'entreprise. La session enregistrée restera disponible en replay pendant 180 jours après l'événement.
Werewolf Therapeutics (Nasdaq: HOWL), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von bedingt aktivierten Therapeutika zur Behandlung von Krebs und immunvermittelten Erkrankungen konzentriert, hat seine Teilnahme an der bevorstehenden 2025 Leerink Partners Global Biopharma Conference bekannt gegeben.
Die Unternehmensführung, einschließlich Daniel J. Hicklin, Ph.D., Präsident und CEO, sowie Randi Isaacs, M.D., Chefärztin, wird an einem geplanten Fireside-Chat teilnehmen, der für Dienstag, den 11. März 2025, von 11:20 bis 11:50 Uhr im Studio 3 angesetzt ist. Die Konferenz findet vom 10. bis 12. März 2025 in Miami, Florida, statt.
Interessierte Parteien können über die Investor-Relations-Website des Unternehmens auf einen Live-Stream der Präsentation zugreifen. Die aufgezeichnete Sitzung bleibt 180 Tage nach der Veranstaltung für eine Wiederholung verfügbar.
- None.
- None.
WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat from 11:20-11:50 AM on Tuesday, March 11, 2025, in Studio 3 at the Leerink Partners Global Biopharma Conference, taking place March 10-12, 2025, in Miami, Florida.
A live webcast link for the Leerink Partners Global Biopharma Conference fireside chat will be available at https://investors.werewolftx.com/news-and-events/events. An archived replay will be available for 180 days following the event.
About Werewolf Therapeutics:
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit www.werewolftx.com.
WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.
Investor Contact
Dan Ferry
LifeSci Advisors
617.430.7576
daniel@lifesciadvisors.com
Media Contact:
Amanda Sellers
Deerfield Group
301.332.5574
amanda.sellers@deerfieldgroup.com
Company Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com
FAQ
When is Werewolf Therapeutics (HOWL) presenting at the 2025 Leerink Partners Conference?
How long will the HOWL presentation webcast be available for replay?
Where can investors watch Werewolf Therapeutics' (HOWL) Leerink conference presentation?
Which Werewolf Therapeutics executives are presenting at the 2025 Leerink Conference?
What is the main focus of Werewolf Therapeutics' (HOWL) research and development?
